Search

everythinglearnresearchcommunity

for

Search:↓

Mycophenolic acid may help hair growth, a combination treatment improves hair thickness in male hair loss, and early treatment of frontal fibrosing alopecia is important.

Cicatricial alopecia causes permanent hair loss and is treated to relieve symptoms and stop progression.

Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.

The document concludes that permanent hair loss conditions are complex, require early specific treatments, and "secondary permanent alopecias" might be a more accurate term than "secondary cicatricial alopecia."

Thyroid disease can cause hair loss and treating thyroid problems might help with hair disorders.

Hair loss patterns differ between males and females due to 5 master regulators and JAK-STAT signaling affects hair growth.

Topical minoxidil helps treat hair loss in teens, but more research needed for safe options.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.

A premenopausal woman had hair loss and skin issues, treated with topical steroids.

There may be a connection between Frontal Fibrosing Alopecia and Lichen Planus Pigmentosus, and more research is needed to confirm this.

Some chemotherapy can cause permanent hair loss.

The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

3% topical minoxidil effectively treats extensive alopecia areata with few side effects.

New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

The document concludes that post-menopausal frontal fibrosing alopecia is a poorly understood condition that does not respond well to common treatments.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.

Treatments for Frontal Fibrosing Alopecia have not been proven effective.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.